glp 1 come from Glucagon-like peptide-1 glp-1_analogs [TUSOM | Pharmwiki]

Holst, Jens Juul (octubre de 2007)

While the research is still in its early stages, many therapeutic applications already appear promising

SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes Cardiovascular Events and All-Cause Mortality in Patients with Type 2 Diabetes Treated with Dipeptidyl Peptidase-4 Inhibitors: An Extensive Meta-Analysis of Randomized Controlled Trials

While incretin-based therapies have been commercially available since 2005, most clinical trials only report short term outcomes

Overall, theoretically, differences in the pharmacokinetic profiles of different GLP-1RAs may have important implications for their efficacy in BAD and perhaps help explain why liraglutide could be superior in reducing symptoms of BAD as compared with the more potent and longer-acting semaglutide

While looking into ways to circumvent this issue, I read up more about "Ozempic"